Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03637660
Other study ID # 17-0101
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 31, 2018
Est. completion date March 20, 2023

Study information

Verified date September 19, 2019
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 4, randomized, open-label, multicenter trial to evaluate the efficacy of a single injected dose of Benzathine Penicillin G (BPG) 2.4 MU (Arm 1) compared to three successive weekly injected doses of BPG 2.4 MU (Arm 2) for treatment of early syphilis in human immunodeficiency virus (HIV)-infected and HIV-uninfected subjects. The study will enroll 560 adults (to achieve 420 evaluable subjects) aged 18 years or older with untreated early syphilis (primary, secondary, or early latent). It will be conducted at 9 sites in the US and last for 48 months with patient participation duration of 12 months. The primary objective is to compare the serological response to therapy in subjects with early (primary, secondary, or early latent) syphilis treated with Benzathine Penicillin G (BPG) 2.4 million units (MU) once or weekly for three successive weeks.


Description:

This is a phase 4, randomized, open-label, multicenter trial to evaluate the efficacy of a single injected dose of Benzathine Penicillin G (BPG) 2.4 MU (Arm 1) compared to three successive weekly injected doses of BPG 2.4 MU (Arm 2) for treatment of early syphilis in human immunodeficiency virus (HIV)-infected and HIV-uninfected subjects. The study will enroll 560 adults (to achieve 420 evaluable subjects) aged 18 years or older with untreated early syphilis (primary, secondary, or early latent). It will be conducted at 9 sites in the US and last for 48 months with patient participation duration of 12 months. The primary objective is to compare the serological response to therapy in subjects with early (primary, secondary, or early latent) syphilis treated with Benzathine Penicillin G (BPG) 2.4 million units (MU) once or weekly for three successive weeks. The secondary objectives are: 1) to determine if the difference in response to therapy between treatment arms by Month 6 differs among subjects with or without HIV infection; 2) to determine the impact of multiple BPG injected doses on subject compliance with study product and adherence to the corresponding scheduled visits; 3) to determine the incidence and manifestations of the Jarisch-Herxheimer reaction among subjects treated for early syphilis with BPG; 4) to collect prospective data up to Month 12 on the serological response to therapy in subjects treated for early syphilis with either BPG regimen; 5) to compare epidemiological characteristics of early syphilis among subjects with or without HIV infection.


Recruitment information / eligibility

Status Completed
Enrollment 249
Est. completion date March 20, 2023
Est. primary completion date September 7, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: 1. Subject is aged 18 years or older. 2. Subject has provided informed consent. 3. Subject has untreated primary*, secondary**, or early latent*** syphilis. *Primary syphilis is characterized by the presence of an ulcerative lesion at a potential site of inoculation (while classically solitary, shallow, painless and with an indurated, clean base, primary lesions may be multiple, may vary considerably in appearance, and/or may not be painless) or by darkfield, acceptable polymerase chain reaction (PCR), or direct fluorescence antibody-T. pallidum (DFA-TP) positive ulcers. **Secondary syphilis is characterized by classical palmar/plantar rash, condylomata lata, mucous patches, etc. or by darkfield, acceptable PCR, or DFA-TP positive lesions. ***Early latent syphilis is characterized by current reactive serologic tests for syphilis (STS) and a documented non-reactive STS, or documented sexual exposure to an individual known to have primary, secondary, or early latent syphilis diagnosed within the last 12 months. 4. Subject either has a newly reactive non-treponemal test (such as an RPR test) or a history of syphilis and a current increase in RPR titer of two or more dilutions (i.e., four-fold). 5. If subject is of childbearing potential, subject has a negative urine or serum pregnancy test. 6. Subject is willing to have an human immunodeficiency virus (HIV) test, participate in HIV counseling, and return to clinic for follow-up. 7. In the opinion of the investigator, subject is able and willing to comply with study procedures, including receipt of three Benzathine Penicillin G (BPG) injected doses if randomized to Arm 2. 8. If female, subject must be of non-childbearing potential* or must be using an acceptable method of birth control** to avoid becoming pregnant. - Non-childbearing potential is defined as being post-menopausal for at least 1 year, status after bilateral tubal ligation, or status after bilateral oophorectomy, or status after hysterectomy. - Subject must agree to avoid becoming pregnant by using one of the following acceptable methods of birth control for the entire duration of participation in the trial: - Intrauterine contraceptive device; OR - Oral contraceptives; OR - Hormonal injections; OR - Hormonal implants; OR - Contraceptive patches; OR - Monogamous relationship with vasectomized partner; OR - Exclusively same-sex relationships; OR - Use of condoms by the male partner; OR - Abstinence Exclusion Criteria: 1. Subject previously enrolled in this trial. 2. Subject has latent syphilis of unknown duration, late latent syphilis, or evidence of neurosyphilis, including ocular syphilis.* *e.g., eye pain/redness, recent ocular change, and/or changes in visual acuity 3. Subject has a known or suspected allergy or hypersensitivity to penicillin or other beta-lactam antibiotics. 4. Subject has a known or suspected sexually transmitted infection (STI) other than syphilis requiring treatment with a drug active against T. pallidum. 5. Subject has used antibiotics* active against T. pallidum in the preceding 30 days. *Note: the use of antimicrobials known to NOT be effective against T. pallidum (e.g., quinolones, sulfonamides, trimethoprim, metronidazole, spectinomycin) will be allowed. 6. Subject has suspected or known ongoing drug use that might interfere with study participation and follow-up treatment. 7. Subject is breastfeeding. 8. Subject has used an investigational drug in the past 30 days that might interfere with safety or efficacy assessment. *If the subject has used any investigational drugs in the past 30 days, contact the Principal Investigator, Division of Microbiology and Infectious Diseases (DMID) Clinical Project Manager, DMID Medical Officer, and FHI 360 to confirm eligibility. 9. Subject has any other condition that, in the opinion of the investigator, would interfere with participation in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Benzathine Penicillin
BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.

Locations

Country Name City State
United States Emory University Hospital Midtown - Emory Clinic Infectious Diseases Atlanta Georgia
United States Johns Hopkins Bayview Medical Center - Infectious Diseases Baltimore Maryland
United States University of Alabama at Birmingham School of Medicine - Infectious Disease Birmingham Alabama
United States Fenway Health - The Fenway Institute Boston Massachusetts
United States University of North Carolina School of Medicine - Center for Infectious Diseases Durham North Carolina
United States Indiana University School of Medicine - Infectious Diseases Indianapolis Indiana
United States Louisiana State University Health Sciences Center New Orleans Louisiana
United States Magee Women's Hospital of UPMC - Reproductive Infectious Disease Research Pittsburgh Pennsylvania
United States University of Washington - Harborview Medical Center - Center for AIDS and STD Seattle Washington
United States Wake Forest Baptist Health - Infectious Diseases Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Number of Participants With a Serological Response by Month 6. Serological response to therapy by Month 6 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 6 visit window (i.e., scheduled visits up to and including the Month 6 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated:
4-fold or greater decline in RPR titer at any visit prior to the end of the Month 6 visit window compared to baseline, OR
RPR-negative at any visit prior to the end of the Month 6 visit window (i.e., seroreversion).
Day 1 to Day 180
Secondary Categorical Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire Gender identity, sexual orientation, sexual partner, sex history in last 60 days Day 1
Secondary Continuous Descriptive Statistics of Sexual History at Baseline Collected Via a Study-specific Questionnaire Sex history in last 60 days Day 1
Secondary Categorical Descriptive Statistics of Socio-epidemiologic Characteristics at Baseline Collected Via a Study-specific Questionnaire Highest level of education completed, stage of syphilis, prior syphilis history Day 1
Secondary Continuous Descriptive Statistics of Socio-epidemiologic Characterictics at Baseline Collected Via a Study-specific Questionnaire Years of formal education Day 1
Secondary Categorical Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire Sex, Ethnicity, Race Day 1
Secondary Continuous Descriptive Statistics of Participant Baseline Demographics Collected Via a Study-specific Questionnaire Age Day 1
Secondary The Number of Participants Who Receive All Assigned Doses Within the Assigned Visit Windows Compliance with study product will be defined as the participant received all assigned doses within the assigned visit windows. A participant is not adherent to study product if they miss at least one dose or receive at least one dose out of the visit window. Through Month 12
Secondary The Number of Participants Who Report Jarisch-Herxheimer Reaction Manifestations Approximately 24 hours after Visit 1, participants were contacted and evaluated for symptoms of a JHR, which included fever, chills, myalgia, weakness, flushing, worsening of skin rash, tachycardia, heart palpitations, arthralgia, nausea, headache, and dizziness, including time of onset and time of resolution of each symptom reported. Day 1 through Day 2
Secondary Number of Participants With Serological Response by Month 6 Among Participants With or Without HIV Infection Serological response to therapy by Month 6 was defined as follows, where available rapid plasma reagin (RPR) results from all visits prior to the end of the Month 6 visit window (i.e., scheduled visits up to and including the Month 6 visit, early termination visit, or any unscheduled visit that occurred prior to the end of month 6 visit window) were evaluated:
4-fold or greater decline in RPR titer at any visit prior to the end of the Month 6 visit window compared to baseline, OR
RPR-negative at any visit prior to the end of the Month 6 visit window (i.e., seroreversion).
Serological response to therapy by Month 6 was examined among participants with and without HIV infection,
Day 1 to Day 180
See also
  Status Clinical Trial Phase
Completed NCT03660488 - Cefixime for Alternative Syphilis Treatment Phase 2
Recruiting NCT05548426 - Linezolid for Syphilis Pilot Study Phase 2
Completed NCT02191527 - Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services in Mozambique N/A
Completed NCT01439503 - Safer Sex Program for Young African-American Men Phase 2
Terminated NCT01540227 - Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.
Completed NCT02257658 - Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM N/A
Completed NCT02611765 - Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study Phase 4
Not yet recruiting NCT06428643 - A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities N/A
Completed NCT03709862 - Global Syphilis Sequencing
Active, not recruiting NCT03310424 - Transcriptomic and Next Generation Sequencing Approaches to Infection With Treponema Pallidum
Completed NCT00207506 - Lay Health Advisors for Sexually Transmitted Disease Prevention Phase 1/Phase 2
Completed NCT00213018 - Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission Phase 2
Recruiting NCT06059443 - mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention N/A
Completed NCT04480749 - Syphilis Self-testing to Expand Test Uptake Among Men Who Have Sex With Men (SST) Phase 4
Not yet recruiting NCT06058286 - MENJAGA: Continuous Quality Improvement for Antenatal HIV, Syphilis and Hepatitis B Testing in Indonesia N/A
Active, not recruiting NCT03980223 - Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Phase 4
Completed NCT01465607 - Implementation of an Efficacious Intervention for High Risk Women in Mexico N/A
Completed NCT00553111 - Video Tool to Promote Knowledge of Syphilis as Facilitator of HIV Transmission N/A
Active, not recruiting NCT06367621 - Retrospective Study of iStatis Syphilis Ab Test (POC)
Completed NCT02445846 - Dual Rapid HIV & Syphilis Tests in Zambia N/A